UPDATE 1-Early data promising for AstraZeneca cancer drug combination

September 27, 2014 11:47 AM

6 0

* Objective response rate in patients 28 percent (Adds comments from researcher, paragraphs 5 and 11)

MADRID, Sept 27 (Reuters) - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page